Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer

JAMA

Volumn 303, Issue 11, 2010, Pages 1037-1045

  Kahn, Katherine L ^a,b   Adams, John L ^a   Weeks, Jane C ^e   Chrischilles, Elizabeth A ^h   Schrag, Deborah ^g   Ayanian, John Z ^i,j   Kiefe, Catarina I ^k   Ganz, Patricia A ^c,d   Bhoopalam, Nirmala ^l   Potosky, Arnold L ^m   Harrington, David P ^f   Fletcher, Robert H ^j,n  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Division of Medical Sciences   (United States)

^f University of Iowa ^*  (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l HINES VA HOSPITAL   (United States)

^m GEORGETOWN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CATHETER THROMBOSIS; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG WITHDRAWAL; ESPIRATORY DISE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEART ARREST; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUROPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77949519818     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.272     Document Type: Article

References (39)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322 (6):352-358.
2. Laurie JA, Moertel CG, Fleming TR, et al; The North Central Cancer Treatment Group and the Mayo Clinic. Surgical adjuvant therapy of large-bowel carcinoma. J Clin Oncol. 1989;7(10):1447-1456.
3. Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma: long term results and evaluation of the indicators of health-related quality of life. Cancer. 1998;82(11):2135-2144.
4. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
5. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091-1097.
6. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer. J Clin Oncol. 2007;25(16): 2198-2204.
7. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27 (19):3109-3116.
8. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850-857.
9. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-1202.
10. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among el-derly patients with node-positive colon cancer. Ann Intern Med. 2002;136(5):349-357.
11. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21(7):1293-1300.
12. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer. JAMA. 2005;294(21):2703-2711.
13. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23 (13):3112-3124.
14. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer. Ann Oncol. 2004;15(9):1330-1338.
15. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer. J Clin Oncol. 2008;26(15):2532-2537.
16. Ayanian JZ, Chrischilles EA, Fletcher RH, et al. Understanding cancer treatment and outcomes. J Clin Oncol. 2004;22(15):2992-2996.
17. Malin JL, Ko C, Ayanian JZ, et al. Understanding cancer patients' experience and outcomes. Support Care Cancer. 2006;14(8):837-848.
18. Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium Web site. http://healthservices.cancer.gov/cancors/. Accessed September 30, 2009.
19. Keating NL, Landrum MB, Rogers SO Jr, et al. Physician factors associated with discussions about endof-life care. Cancer. 2010;116(4):998-1006.
20. American Joint Committee on Cancer. AJCC Cancer Staging Atlas. Chicago, IL: Springerlink; 2006.
21. Piccirillo JF, Costas I, Grove L. A critical appraisal of the use of ICD-9-CM codes to classify comorbidity and complications. J Registry Manag. 2003; 30(4):117-122.
22. Piccirillo JF, Costas I. The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec. 2004;66(4):180-185.
23. StataCorp. Stata Statistical Software: Release 9. College Station, TX: StataCorp; 2005.
24. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652-659.
25. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570.
26. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
27. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295-300.
28. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer. J Clin Oncol. 2005;23(34):8671-8678.
29. Dencausse Y, Hartung G, Sturm J, et al. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie. 2002;25(5):426-430.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
31. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24 (15):2368-2375.
32. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1-39.
33. Miniño AM, Heron MP, Murphy SL, Kochanek KD; Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55(19):1-119.
34. Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist. 2008;13(4): 390-402.
35. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer. J Clin Oncol. 2009;27(6):872-877.
36. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials. JAMA. 2003;290(12):1624-1632.
37. Kahn KL. Moving research from bench to bedside to community. J Clin Oncol. 2008;26(4):523-526.
38. Adjuvant! Online: decision making tools for health care professionals. http://www.adjuvantonline.com/index.jsp. Accessed February 4, 2010.
39. Cancer Therapy Evaluation Program: Common Toxicity Criteria. National Cancer Institute. http://ctep.cancer.gov/reporting/ctc.html. Accessed February 7, 2010.